| Literature DB >> 35458791 |
Senty Vun-Sang1, Kenneth Francis Rodrigues1, Urban J A Dsouza2, Mohammad Iqbal1.
Abstract
Local tribes use the leaves of Ficus lepicarpa B. (Moraceae), a traditional Malaysian medicine, as a vegetable dish, a tonic, and to treat ailments including fever, jaundice and ringworm. The purpose of this study was to look into the possible therapeutic effects of F. lepicarpa leaf extract against carbon tetrachloride (CCl4)-induced liver damage in rats. The DPPH test was used to measure the antioxidant activity of plants. Gas chromatography-mass spectrometry was used for the phytochemical analysis (GCMS). Six groups of male Sprague-Dawley rats were subjected to the following treatment regimens: control group, CCl4 alone, F. lepicarpa 400 mg/kg alone, CCl4 + F. lepicarpa 100 mg/kg, CCl4 + F. lepicarpa 200 mg/kg and CCl4 + F. lepicarpa 400 mg/kg. The rats were euthanized after two weeks, and biomarkers of liver function and antioxidant enzyme status were assessed. To assess the extent of liver damage and fibrosis, histopathological and immunohistochemical examinations of liver tissue were undertaken. The total phenolic content and the total flavonoid content in methanol extract of F. lepicarpa leaves were 58.86 ± 0.04 mg GAE/g and 44.31 ± 0.10 mg CAE/g, respectively. F. lepicarpa's inhibitory concentration (IC50) for free radical scavenging activity was reported to be 3.73 mg/mL. In a dose-related manner, F. lepicarpa was effective in preventing an increase in serum ALT, serum AST and liver MDA. Histopathological alterations revealed that F. lepicarpa protects against the oxidative stress caused by CCl4. The immunohistochemistry results showed that proinflammatory cytokines (tumour necrosis factor-α, interleukin-6, prostaglandin E2) were suppressed. The antioxidative, anti-inflammatory, and free-radical scavenging activities of F. lepicarpa can be related to its hepatoprotective benefits.Entities:
Keywords: F. lepicarpa; carbon tetrachloride; oxidative stress; proinflammatory cytokines
Mesh:
Substances:
Year: 2022 PMID: 35458791 PMCID: PMC9029070 DOI: 10.3390/molecules27082593
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Phytochemical constituents of leaf extract of F. lepicarpa.
| Phytochemical Constituents | Presence (+) or Absence (−) |
|---|---|
| Alkaloids (Wagner’s test) | − |
| Flavonoids (alkaline reagent test) | + |
| Tannins (Braymer’s test) | − |
| Saponin (foam test) | + |
| Phenols (ferric chloride test) | + |
| Steroids (Liebermann–Burchard test) | + |
| Anthraquinones | − |
| Phytosterols | + |
| Triterpenoids (Salkowki’s test) | + |
Figure 1Chromatogram of GC-MS analysis of F. lepicarpa.
Phytochemical contents of F. lepicarpa identified using GCMS.
| No. | Ret. Time (min) | Compound | Area (%) |
|---|---|---|---|
| 1. | 9.595 | Homovanillyl alcohol | 0.24 |
| 2. | 9.773 | 2,5-Dimethoxy-4-ethylamphetamine | 0.16 |
| 3. | 12.756 | Benzene, 1,2-dimethoxy-4-(1-propenyl)- | 0.16 |
| 4. | 13.111 | Succinic acid, non-4-enyl undecyl ester | 0.42 |
| 5. | 13.832 | Cyclohexene, 3-(2-methylpropyl)- | 0.07 |
| 6. | 14.637 | Hexadecanoic acid, methyl ester | 0.11 |
| 7. | 17.865 | Phytol | 0.13 |
| 8. | 27.762 | Cycloprop [ | 0.13 |
| 9. | 27.880 | 2,2-Dimethyl-3-(3,7,16,20-tetramethyl-heneicosa-3,7,11,15,19-pentaenyl)-oxirane | 0.44 |
| 10. | 28.660 | Squalene | 2.85 |
| 11. | 30.727 | Octasiloxane, 1,1,3,3,5,5,7,7,9,9, 11,11,13,13,15,15-hexadecamethyl- | 0.16 |
| 12. | 31.176 | 5,5′-Bis [2 -(4-aminophenyl)-1H-1,3-benzimidazol] | 0.18 |
| 13. | 31.371 | .gamma.-Tocopherol | 0.27 |
| 14. | 31.736 | Stigmastan-3,5-diene | 0.55 |
| 15. | 33.778 | 3-Quinolinecarboxylic acid, 6,8-difluoro-4-hydroxy-, ethyl ester | 0.20 |
| 16. | 33.981 | 1H-Indole, 1-methyl-2-phenyl- | 0.19 |
| 17. | 34.083 | Silane, trimethyl [5 -methyl-2-(1-methylethyl)phenoxy]- | 0.167 |
| 18. | 34.862 | .beta.-Sitosterol | 4.44 |
| 19. | 35.159 | 5(1H)-Azulenone, 2,4,6,7,8,8a-hexa hydro-3,8-dimethyl-4-(1-methylethylidene)-, (8S-cis)- | 0.46 |
| 20. | 35.278 | Benzo[h]quinoline, 2,4-dimethyl- | 1.67 |
| 21. | 35.650 | .alpha.-Amyrin | 2.62 |
| 22. | 35.820 | Lupeol | 4.16 |
| 23. | 36.260 | 6.beta.Bicyclo[4.3.0]nonane, 5.beta.-iodomethyl-1.beta.-isopropenyl-4.alpha.,5.alpha.-dimethyl-, | 3.02 |
| 24. | 36.506 | Urs-12-en-24-oic acid, 3-oxo-, methyl ester, (+)- | 9.80 |
| 25. | 37.032 | Acetic acid, 3-hydroxy-6-isopropenyl-4,8a-dimethyl-1,2,3,5,6,7,8,8a-octahydronaphthalen-2-yl ester | 13.69 |
| 26. | 37.150 | 12-Oleanen-3-yl acetate, (3.alpha.)- | 21.09 |
| 27. | 38.006 | 3-Quinolinecarboxylic acid, 6,8-difluoro-4-hydroxy-,ethyl ester | 1.75 |
| 28. | 38.489 | A`-Neogammacer-22(29)-en-3-ol, acetate, (3.beta.,21.beta) | 0.77 |
| 29. | 39.048 | 5-Methyl-2-phenylindolizine | 0.06 |
| 30. | 41.302 | 1H-Tndol-2-carboxylic acid, 6-(4-ethoxyphenyl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-, isopropyl ester | 0.15 |
Final body weight and liver index of rats in different treatment groups.
| Treatment Group | Initial Body Weight (g) | Final Body Weight (g) | Percentage Increase of Body Weight (%) | Liver Index (%) |
|---|---|---|---|---|
| Control | 227.77 ± 6.61 | 265.33 ± 13.63 | 16.49 | 3.08 ± 0.29 |
| CCl4 (1 mL/kg bwt) | 229.17 ± 7.24 | 237.50 ± 2.55 | 3.64 | 4.93 ± 0.37 |
| 228.63 ± 5.11 | 241.81 ± 2.93 | 5.76 | 4.15 ± 0.29 | |
| 230.83 ± 5.75 | 247.77 ± 1.98 | 7.34 | 4.10 ± 0.20 | |
| 232.58 ± 6.41 | 252.33 ± 3.11 | 8.49 | 4.03 ± 0.29 | |
| 229.67 ± 7.20 | 265.75 ± 14.04 | 15.71 | 3.05 ± 0.23 |
All values represent the mean ± SEM of six animals (n = 6).
Effects of F. lepicarpa on hepatic serum AST & ALT levels following CCl4 treatment.
| Treatment Group | ALT Enzyme Activity (U/L) | AST Enzyme Activity (U/L) |
|---|---|---|
| Control | 6.56 ± 0.06 | 11.58 ± 0.01 |
| CCl4 (1 mL/kg bwt) | 47.03 ± 0.33 * | 42.28 ± 0.59 * |
| 23.75 ± 0.41 | 24.20 ± 0.33 | |
| 14.63 ± 0.37 ** | 19.21 ± 0.34 | |
| 11.26 ± 0.06 ** | 14.41 ± 0.02 ** | |
| 6.64 ± 0.07 ** | 11.21 ± 0.02 ** |
All values represent the mean ± SEM of six animals (n = 6). * Values differ significantly from the corresponding values of control group (p < 0.05). ** Values differ significantly from the corresponding values of the CCl4 alone treated group (p < 0.05).
Effects of F. lepicarpa on hepatic GSH and MDA levels following CCl4 treatment.
| Treatment Group | GSH (µmol/g Tissue) | MDA Formation |
|---|---|---|
| Control | 9.18 ± 0.05 | 22.22 ± 0.01 |
| CCl4 (1 mL/kg bwt) | 2.33 ± 0.04 * | 69.51 ± 0.12 * |
| 3.87 ± 0.04 | 59.18 ± 0.04 | |
| 4.03 ± 0.05 ** | 49.34 ± 0.07 | |
| 5.41 ± 0.07 ** | 36.74 ± 0.02 ** | |
| 8.32 ± 0.05 ** | 21.31 ± 0.02 ** |
All values represent the mean ± SEM of six animals (n = 6). * Values differ significantly from the corresponding values of control group (p < 0.05). ** Values differ significantly from the corresponding values of the CCl4 alone treated group (p < 0.05).
Protective effects of F. lepicarpa on activities of hepatic antioxidant enzymes.
| Treatment Group | GPx | GR | GST | QR (nmol Dichloroindophenol Reduced/min/mg Protein) |
|---|---|---|---|---|
| Control | 865.25 ± 0.14 | 215.46 ± 0.30 | 330.18 ± 0.04 | 114.06 ± 0.12 |
| CCl4 (1 mL/kg bwt) | 389.77 ± 0.20 * | 71.71 ± 0.24 * | 111.85 ± 0.04 * | 59.08 ± 0.10 * |
| 400.86 ± 0.11 | 104.86 ± 0.25 | 177.68 ± 0.08 | 80.89 ± 0.11 | |
| 523.58 ± 0.14 ** | 145.89 ± 0.28 ** | 222.04 ± 0.04 ** | 100.30 ± 0.11 ** | |
| 542.32 ± 0.06 ** | 182.36 ± 0.35 ** | 249.04 ± 0.03 ** | 102.04 ± 0.12 ** | |
| 760.50 ± 0.06 ** | 203.84 ± 0.27 ** | 296.49 ± 0.02 ** | 106.38 ± 0.12 ** |
All values represent the mean ± SEM of six animals (n = 6). * Values differ significantly from the corresponding values for normal control (* p < 0.05). ** Values differ significantly from the corresponding values for the CCl4 alone treated control (** p < 0.05).
Figure 2Photomicrographs of rat liver sections stained with haematoxylin and eosin from each group. Total magnifications 10×. (A) Control group, normal histology. (B) CCl4 (1.0 mL/kg bwt)-induced necrosis, fatty acid degeneration, derangement of hepatocytes. (C) F. lepicarpa (100 mg/kg bwt + CCl4); slight repairing of hepatocytes. (D) F. lepicarpa (200 mg/kg bwt + CCl4) repairing of hepatocytes. (E) F. lepicarpa (400 mg/kg bwt + CCl4); repairing of hepatocytes. (F) F. lepicarpa (400 mg/kg bwt) (normal histology).
Figure 3The effect of F. lepicarpa extract on the proinflammatory marker tumour necrosis factor-alpha (TNF-α). Total magnifications 10×. (A) Control group, normal. (B) CCl4 (1.0 mL/kg bwt), high expression of TNF-α. (C) F. lepicarpa (100 mg/kg bwt + CCl4), low expression of TNF-α. (D) F. lepicarpa (200 mg/kg bwt + CCl4), low expression of TNF-α. (E) F. lepicarpa (400 mg/kg bwt + CCl4), low expression of TNF-α. (F) F. lepicarpa (400 mg/kg bwt, plant control), normal.
Figure 4The effect of F. lepicarpa extract on the proinflammatory marker interleukin 6 (IL-6). Total magnifications 10×. (A) Control group, normal. (B) CCl4 (1.0 mL/kg bwt), high expression of IL-6. (C) F. lepicarpa (100 mg/kg bwt + CCl4), low expression of IL-6. (D) F. lepicarpa (200 mg/kg bwt + CCl4), low expression of IL-6. (E) F. lepicarpa (400 mg/kg bwt + CCl4), low expression of IL-6. (F) F. lepicarpa (400 mg/kg bwt, plant control), normal.
Figure 5The effect of F. lepicarpa extract on the proinflammatory marker prostaglandin E2 (PGE2). Total magnifications 10×. (A) Control group, normal. (B) CCl4 (1.0 mL/kg bwt), high expression of PGE2. (C) F. lepicarpa (100 mg/kg bwt + CCl4), low expression of PGE2. (D) F. lepicarpa (200 mg/kg bwt + CCl4), low expression of PGE2. (E) F. lepicarpa (400 mg/kg bwt + CCl4), low expression of PGE2. (F) F. lepicarpa (400 mg/kg bwt, plant control), normal.